BLFS Stock Cash Flow Statements

BioLife Solutions Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

BioLife Solutions Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2018-12-31	2011-12-31

cash flows from operating activities
net income	-448,000	12,459,000	-1,703,000	-20,719,000	-10,221,000	-13,382,000	-29,132,000	-10,199,000	-13,714,000	-50,228,000	-9,957,000	-72,554,000	-7,066,000	-14,472,000	79,000	7,876,000	-1,118,000	-2,128,000	-1,133,000	-16,380,000	22,308,000	892,571	-411,170
adjustments to reconcile net income to net cash from operating activities
depreciation	682,000	937,000	1,407,000	1,452,000	1,364,000	1,468,000	1,922,000	2,003,000	1,721,000	1,719,000	1,799,000	1,604,000	1,653,000	1,628,000	1,140,000	1,118,000	777,000	581,000	481,000	560,000	413,000	93,073
amortization of intangible assets	702,000	767,000	910,000	910,000	914,000	915,000	1,355,000	1,452,000	1,459,000	1,461,000	2,511,000	2,862,000	2,863,000	2,862,000	2,525,000	1,882,000	933,000	933,000	706,000	706,000	688,000
stock-based compensation	4,153,000	10,692,000	5,329,000	8,719,000	6,183,000	8,333,000	9,117,000	6,857,000	7,363,000	7,663,000	6,299,000	5,973,000	5,399,000	5,065,000	4,867,000	2,519,000	1,505,000	2,163,000	1,560,000	1,145,000	1,113,000
non-cash lease expense	312,000	159,000				-90,000	466,000	-390,000	418,000	2,461,000	-283,000	784,000	524,000	258,000	748,000
deferred income tax expense	6,000			0	5,000		23,000	0	13,000
accretion of available-for-sale investments	-105,000		-89,000	-136,000	-182,000
gain on disposal of property and equipment
loss on disposal of assets held for rent	187,000	109,000	123,000	137,000	198,000	151,000								276,000	231,000	37,000	65,000
change in operating assets and liabilities, net of effects of acquisitions
accounts receivable, trade	1,000	-1,233,000	208,000	-1,939,000	65,000	5,914,000	2,346,000	3,479,000	3,612,000	-1,315,000	-1,310,000	-7,045,000	-1,083,000	-2,992,000	1,354,000	-5,831,000	-2,663,000	-966,000	-1,744,000	3,853,000	-2,929,000	-345,973	-88,466
inventories	1,447,000	-1,343,000	317,000	1,765,000	42,000	-102,000	-4,177,000	2,152,000	-6,425,000	-1,156,000	-413,000	-3,135,000	-1,855,000	1,351,000	-2,520,000	1,348,000	-65,000	-564,000	-147,000	-61,000	143,000	-597,819	-30,830
prepaid expenses and other assets	181,000		-1,406,000	528,000	2,392,000		138,000	-1,844,000	661,000		136,000	-1,467,000	-25,000
accounts payable	-828,000	1,165,000	-373,000	1,190,000	-1,956,000	-5,045,000	1,301,000	-4,838,000	157,000	4,029,000	-213,000	-171,000	-3,231,000	650,000	4,158,000	-3,394,000	604,000	433,000	-667,000	-498,000	561,000	-353,875	92,661
accrued expenses and other current liabilities	-4,252,000	6,581,000	262,000	2,409,000	-2,767,000	3,694,000	-1,802,000	-261,000	371,000	1,343,000	1,477,000	41,000	-1,074,000	-1,406,000	1,352,000	-5,571,000	1,689,000				304,000
sales taxes payable	-327,000	-84,000	-501,000	-408,000	20,000	-19,000	412,000	408,000	510,000
other	16,000		-1,000	112,000	-377,000		181,000	-3,000	-50,000	-136,000	102,000	217,000	-17,000	-151,000	329,000	174,000	1,000	181,000			-402,000
net cash from operating activities	1,727,000	1,645,000	4,802,000	6,459,000	-4,475,000	2,311,000	-4,379,000	-7,718,000	-2,712,000	7,857,000	1,496,000	-9,917,000	-7,924,000	-774,000	2,083,000	-7,722,000	1,820,000	2,257,000	-502,000	4,203,000	687,000	585,480	-192,795
capex	377,000	-752,000	-1,319,000	-995,000	-356,000	-4,686,000	1,738,000	-126,000	-2,948,000	-5,631,000	-887,000	-1,946,000	-1,443,000	-1,674,000	-2,412,000	-2,687,000	-1,720,000	-1,591,000	-119,000	-82,000	-140,000	-156,033	0
free cash flows	2,104,000	893,000	3,483,000	5,464,000	-4,831,000	-2,375,000	-2,641,000	-7,844,000	-5,660,000	2,226,000	609,000	-11,863,000	-9,367,000	-2,448,000	-329,000	-10,409,000	100,000	666,000	-621,000	4,121,000	547,000	429,447	-192,795
cash flows from investing activities
purchases of available-for-sale securities	-30,324,000		-5,302,000	-4,338,000	-6,374,000		-6,960,000	-7,526,000	-8,202,000
proceeds from sale of available-for-sale securities	573,000	909,000	819,000	817,000	973,000	498,000	1,119,000	1,328,000	524,000
maturities of available-for-sale securities	3,000,000	2,800,000	4,350,000	5,250,000	6,000,000	10,250,000	9,900,000	17,650,000	14,900,000
purchases of assets held for rent	-250,000	-40,000	-434,000	-1,130,000	-464,000	-1,403,000	-901,000	-1,551,000	-1,001,000	-1,267,000	-1,495,000	40,000	-814,000
purchases of property and equipment	-175,000	-762,000	-1,114,000	-995,000	-356,000	-981,000	-1,496,000	-609,000	-3,295,000	-4,448,000	-2,446,000	-2,035,000	-1,456,000	-1,566,000	-2,412,000	-2,687,000	-1,720,000
net cash from investing activities	-27,176,000	73,637,000	-1,681,000	-13,435,000	-221,000	3,957,000	1,662,000	9,292,000	2,926,000	-14,894,000	-15,883,000	-25,070,000	-2,270,000	-2,542,000	-2,007,000	-4,216,000	-4,427,000	-22,057,000	-975,000	-456,000	-1,227,000	-160,932
cash flows from financing activities
payments on equipment loans		-926,000	-214,000	-227,000	-241,000	185,000	-127,000	-129,000	-127,000	-128,000	-123,000	-122,000	-125,000
payments on term loans	-2,500,000
payments on financed insurance premium	-502,000	-667,000	-483,000	-520,000	-727,000	-712,000	-1,761,000	677,000	-569,000	-561,000	-356,000	-153,000	-305,000	-335,000	-511,000
net cash from financing activities	-2,992,000	-4,086,000	-1,041,000	-704,000	-952,000	9,841,000	608,000	704,000	-562,000	-625,000	17,411,000	-289,000	-181,000	-2,105,000	-1,058,000	-831,000	1,216,000	1,272,000	80,582,000	19,732,000	492,000	-2,147,904
net decrease in cash, cash equivalents, and restricted cash	-28,441,000				-5,648,000		-2,109,000	2,278,000	-348,000	-7,662,000	3,024,000	-35,276,000	-10,375,000				-1,391,000
cash, cash equivalents, and restricted cash – beginning of period	95,386,000		0	0	35,438,000	0	0	0	19,473,000	0	0	0	69,870,000	0	0
effects of currency translation on cash, cash equivalents, and restricted cash			36,000			63,000	-56,000	17,000	11,000	68,000	14,000	-168,000	-22,000	140,000	-166,000
cash, cash equivalents, and restricted cash – end of period	66,945,000		2,116,000			16,172,000	-2,165,000	2,295,000	19,136,000	-7,594,000	3,038,000	-35,444,000	59,473,000	-5,281,000	-1,148,000
non-cash investing and financing activities
purchase of property and equipment not yet paid	552,000	10,000	-205,000			-3,705,000	3,234,000	483,000	347,000	-1,183,000	1,559,000	89,000	13,000	-108,000								4,899
unrealized gains on currency translation
unrealized gains on available-for-sale securities	-9,000
cash interest paid	265,000	372,000	407,000			533,000	459,000	438,000	497,000	356,000	109,000	30,000	91,000
impairment of intangible assets						0
impairment of long-lived assets						0
gain on settlement of global cooling escrow
amortization of loan costs						0	0	0	13,000
deferred income tax benefit										-301,000	-599,000			-2,587,000	-4,988,000
change in fair value of contingent consideration						-415,000	-1,580,000	-918,000	720,000	-1,406,000	2,347,000	-2,360,000	-3,335,000	1,789,000	-140,000	1,717,000	-491,000	3,103,000	-2,000	-1,463,000	-63,000
change in fair value of investments																		-209,000
accretion of investments						-213,000			-390,000
loss on disposal of property and equipment						406,000	12,000	147,000	68,000	691,000	19,000	17,000	18,000										-283
net gain on disposal of subsidiaries
change in operating assets and liabilities
prepaid expenses and other current assets														1,033,000	-601,000	2,318,000	52,000	-43,000	-188,000	-61,000	317,000	-55,394
warranty liability		-50,000	4,000	-424,000	-58,000	-357,000	-221,000	-459,000	583,000	-55,000	-355,000
investment in available-for-sale securities										-17,349,000	-12,692,000
purchases of intangible assets
proceeds from sale of scisafe and cbs
payments on divestiture of global cooling		0	0
proceeds from term loan
payments on term loan
issuance of common stock
fees paid related to issuance of common stock										-1,000			-50,000	0
proceeds from exercise of common stock options						137,000	64,000	181,000	125,000	16,000	6,000	44,000	257,000	401,000	409,000	365,000	243,000	443,000	245,000	293,000	490,000
proceeds from financed insurance premium		0				0
net increase in cash and cash equivalents																				23,479,000	-48,000	-1,723,356	-3,253
cash and cash equivalents – beginning of period
effects of currency translation on cash and cash equivalents
cash and cash equivalents – end of period
assets acquired under operating leases		531,000	4,993,000			1,760,000
assets acquired under finance leases
unrealized (gain) loss on available-for-sale securities
unrealized gain on currency translation
cashless issuance of scisafe earnout shares						0	0				1,000
returned shares from settlement of global cooling escrow						0
settlement of global cooling escrow							0
deferred income tax (benefit) expense
change in fair value of equity investments			0
(gain) loss on disposal of property and equipment			4,000	-52,000	-14,000
loss on disposal of global cooling			0
proceeds from exercises of common stock options			46,000
assets acquired under financing leases
non-cash lease (benefit) expense				-56,000	-83,000
net increase in cash, cash equivalents, and restricted cash														-5,421,000	-982,000
unrealized gains and losses on currency translation
unrealized gains and losses on available-for-sale securities							-7,000	2,000	-39,000
change in fair value of warrant liability														0	0	0	121,000	866,000	1,005,000	16,442,000	-21,914,000
gain on acquisition of sexton biotechnologies, inc.														0
forgiveness of loans payable
cash acquired in acquisition of global cooling, inc. and sexton biotechnologies, inc.														0
proceeds from sale of equipment														-17,000	21,000	-2,000	3,000	32,000
proceeds from equipment loans														-90,000	358,000	230,000	1,052,000
proceeds from line of credit														856,000	14,650,000
payments on line of credit														-2,879,000	-15,919,000
cashless exercise of warrants reclassified from warrant liability to common stock														0	0
stock issued as consideration to acquire global cooling, inc. and sexton biotechnologies, inc.														0
proceeds from term loans
amortization of investments
gain on disposal of assets held for rent
fees incurred for registration filings
equipment acquired under operating leases								0	880,000	0	0	0	243,000	-96,000	0	5,739,000	1,232,000
loss / (gain) on disposal of assets held for rent									218,000
stock issued for services																		30,000
sales taxes payable
payments related to the acquisition of scisafe, net of cash acquired
investment in ivexsol preferred stock
investment in panthera cryosolutions
deposits on property and equipment																	-672,000
deposits on assets held for rent
proceeds from sale of marketable securities
maturities of marketable securities
proceeds from paycheck protection program ("ppp") loan
payoff of ppp loan																		0	0
payments of contingent consideration																		0	0
proceeds from sale of common stock, net of 6.2 million of costs in 2020
proceeds from exercise of warrants																		0	16,000	15,000	9,000
equipment acquired under finance leases														0	0	0	440,000
unrealized gains and losses on available-for-sale-securities
reclassification of warrant liabilities to equity upon exercise
stock issued as consideration to acquire scisafe
stock issued as bonus consideration																		0	0
intangible asset impairment charges											0
(gain) loss on disposal of assets held for rent											633,000
cash acquired in acquisition of global cooling, inc.
stock issued as consideration to acquire global cooling, inc.
deferred income tax benefits													-599,000
(gain) / loss on disposal of assets held for rent													-96,000
reclassification of property and equipment, net to assets held for rent																	27,000
income from equity method investment in savsu
gain on acquisition of savsu
cash acquired in acquisition of savsu
acquisition of astero bio, net of cash acquired
payments related to the acquisition of cbs
investment in sexton
investment in ivexsol convertible debt
stock issued as consideration to acquire savsu
stock issued as consideration to acquire assets of cbs
purchases of assets held for lease															-1,132,000	-2,242,000	-2,038,000
financing costs paid in a prior period
stock issued as a prepayment of services
purchase of equipment with debt																			137,000			396
deferred financing costs not yet paid
non cash lease expense																	410,000	282,000	155,000	152,000	148,000
cash, cash equivalents, and restricted cash – beginning of year																	90,456,000
cash, cash equivalents, and restricted cash – end of year																	89,065,000
cashless exercise of warrants reclassed from warrant liability to common stock																	2,901,000	0	0
payments related to the acquisition of cbs
purchase of property and equipment																		-1,591,000	-119,000	-105,000	-146,000	-160,932
purchase of assets held for lease
deposits on assets held for lease
proceeds from ppp loan																		0	0
proceeds from sale of common stock, net of 6.2 million of costs																		-130,000
payment of costs related to stock issuance
other payables
accrued compensation and other current liabilities																			512,000			292,347
payments related to the scisafe acquisition
cash acquired on acquisition of savsu
payments related to the astero bio acquisition, net of cash acquired
investment in ivexsol
purchase of assets held for rent																			-359,000	-351,000	-1,081,000
payments of costs related to stock issuance
net increase in cash, cash equivalents and restricted cash
cash, cash equivalents and restricted cash - beginning of period
cash, cash equivalents and restricted cash - end of period
reclassification of warrant liability to equity upon exercise																			53,000	36,000	21,000
purchase of property & equipment not yet paid																			0	23,000	6,000
stock issued as prepayment of services
proceeds from sale of common stock, net of fees
cash and cash equivalents - beginning of period																				0	6,448,000
cash and cash equivalents - end of period																				23,479,000	6,400,000
gain from equity method investment in savsu
stock issued as 2019 bonus payout																					314,000
other liabilities
investment in savsu																						0
stock issue from private equity transaction
payments for redemption of preferred stock																						-3,187,000
payments of preferred stock dividends																						-130,242
cash and cash equivalents – beginning of year
cash and cash equivalents – end of year
stock issued for services in prior period included in liabilities at prior year-end
receivables converted to equity investment in savsu																						-103
legal fees for private equity transaction not yet paid																						1,500
stock-based compensation expense																						388,055
amortization of deferred rent related to lease incentives																						-31,752
amortization of operating lease liability
interest expense – finance type lease
increase in
other assets
proceeds from private equity transaction																						6
payment of costs related to stock issuances
payments on equipment loan																						-2,733
payments on finance lease obligations
proceeds from exercise of common stock options and warrants																						1,175,753
series a preferred stock dividends accrued not yet paid
stock issued for services provided in prior period included in liabilities at year-end
financing costs not yet paid
income from equity-method investment in savsu																						308,757
deferred rent																						-4,510
investment in equity investment savsu
payments on capital lease obligations
payments on capital lease obligation/finance lease
cash received in advance of issuance of stock on warrant exercises
write off of deferred financing costs
amortization of debt discount
accrued interest
proceeds from note payable to related party
payments on capital lease obligation
payments related to stock issuance
deferred costs paid related to potential stock issuance
cash and cash equivalents - beginning of year
cash and cash equivalents - end of year
preferred stock issued to convert related party note payable and accrued interest
capital lease obligations incurred for purchase of equipment
write-off of deferred financing costs
proceeds from related party debt
payments of costs related to stock issuances
deferred costs related to potential stock issuance
preferred stock issued on conversion of related party note payable and accrued interest
capital lease obligations incurred for purchases of equipment
preferred stock issuance costs not yet paid
accrued interest, related party
proceeds from note payable
deferred costs related to security issuance
non-cash financing activity
deferred costs related to security issuance not yet paid as of quarter end
adjustments to reconcile net income to net cash provided by/(used in) operating activities
loss on deconsolidation of biologistex
accretion and amortization on available for sale investments
net cash provided by/(used in) operating activities
sales/maturities of available-for-sale investments
costs associated with internal use software development
net cash provided by/(used in) investing activities
payments related to preferred stock issuance
net increase/(decrease) in cash and cash equivalents
stock issued for services in prior period included in liabilities at year-end
debt discount related to warrants
deferred costs related to potential stock issuances not yet paid
sales of available-for-sale investments
costs incurred for capitalized internal use software not paid as of quarter end
preferred stock dividends accrued
amortization debt discount
option exercises for which cash not yet received as of quarter end
purchase of available-for-sale investments
net decrease in cash and cash equivalents
costs incurred for capitalized internal use software not paid as of year-end
proceeds from issuance of common stock on exercise of common stock options not received as of year-end
deferred costs related to stock issuance not yet paid
accrued interest, related parties																							173,528
purchases of available-for-sale investments
net provided by investing activities
non-cash investing activity
amortization of deferred financing costs																							27,342
lease incentives, net of amortization of deferred rent related to lease incentives
cash received from sale of property and equipment
proceeds from sale of common stock, net of expenses
acquisition of intangible asset from non-controlling interest
conversion of notes payable and related party accrued interest to equity, net of unamortized deferred finance costs
deferred revenue																							-5,000
proceeds from the sale of property and equipment
non-cash investing activities
non-cash financing activities
lease incentives received from landlord, net of amortization of deferred rent related to lease incentives
stock to be issued for services
purchase of available-for-sale investments, net of sales
proceeds from notes payable
deferred financing costs from issuance of warrants																							0
amortization of deferred rent related to lease incentives, net of amount received from landlord
lease incentive received from landlord, net of amortization
prepaid expenses and other current assets and long-term deposits
accrued compensation and other incomes and other current liabilities
cash flows from financing activity
net cash from financing activity																							225,000
depreciation and amortization
share-based compensation expense
accrued expenses and compensation
cash flows from investing activity
purchase of property and equipment, net of proceeds from disposals
net cash from investing activity
proceeds from promissory notes payable, related parties
proceeds from exercise of options
other receivable
accrued compensation and other incomes
accrued expenses
non-cash items:
transfer of accrued interest to promissory notes payable
decrease in restricted cash
principal payments on note payable
collection of stock subscriptions receivable
stock issued in consideration for financing fees related to promissory notes payable
transfer of accrued interest, related parties, to promissory notes payable, related parties
stock issued in consideration for financing fees related to promissory notes payable, related parties

We provide you with 20 years of cash flow statements for BioLife Solutions stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BioLife Solutions stock. Explore the full financial landscape of BioLife Solutions stock with our expertly curated income statements.

The information provided in this report about BioLife Solutions stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.